No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

L G Unveils First Oxide-Based TFT Digital X-Ray Detector, New 3MP Diagnostic Monitor at RSNA 2021

Editor: What To Know

  • Each of these products is not available for sale in the United States and may not be ordered for sale, lease or distribution in commerce, or sold, leased or distributed in commerce, until proper authorization is obtained.
  • LG Business Solutions USA is introducing a new oxide-based thin-film-transistor Digital X-ray Detector (DXD) and 21-inch 3MP diagnostic monitor this week in Chicago at RSNA 2021, the annual meeting of the Radiological Society of North America.
  • The 21HQ513D-B IPS display is designed to facilitate precise review of MRI and CT images through Focus View, allowing users to review specific parts of an image more closely with magnification and brightness adjustment.
  • LG Business Solutions USA is introducing a new oxide-based thin-film-transistor Digital X-ray Detector (DXD) and 21-inch 3MP diagnostic monitor this week in Chicago at RSNA 2021, the annual meeting of the Radiological Society of North America.*

The wireless 14-x17-inch DXD (model 14HQ901G*) will utilize a new oxide-based TFT design to deliver high Detective Quantum Efficiency (DQE), while the 21-inch diagnostic monitor (model 21HQ513D-B*) will introduce localized brightness control to optimize radiological image review, analysis and diagnosis. Both models are on display in LG’s RSNA booth #2559.

“LG is committed to innovating new products that help medical professionals provide the best care possible,” said Brian Fabrizio, medical information displays team leader at LG Business Solutions USA. “Underscoring that commitment, the pending launch of our new DXD and 3MP diagnostic monitor is expected to deliver new capabilities and efficiencies to practitioners.”

The new LG DXD will feature an oxide-based thin-film transistor (TFT) with electron transfer speeds almost 30 times faster than a conventional a-Si TFT. By increasing the Csl thickness of the 14HQ901G from 300um to 500um, LG has also improved the DQE of the new oxide-based TFT by 28 percent at 1 lp/mm, compared to 14HK701G. This DXD also will provide a robust design with concave edges and convenient grips built to withstand a 1.5 meter drop.

The new DXD model is expected to feature LG Acquisition Workstation Software version 3.0,* which can analyze X-rays then inform the medical provider of any abnormalities and provide an abnormality score with a colored heat map or contour that marks any lesions detected. Images sent directly from the DXD to a connected workstation with LG Acquisition Workstation Software version 3.0 would be viewed within seconds, allowing users to obtain X-ray images with ease. Additionally, LG SW Grid estimates and corrects scattered radiation.

The soon-to-be-released 3-megapixel, 21.3-inch high-brightness diagnostic monitor will feature advanced localized brightness control and resolution of 1536 x 2048 pixels for displaying radiological images. The 21HQ513D-B IPS display is designed to facilitate precise review of MRI and CT images through Focus View, allowing users to review specific parts of an image more closely with magnification and brightness adjustment.

The portrait-oriented monitor is designed to provide max brightness of 1100 nits with an 1800:1 contrast ratio to enable precise review of digital images while helping to illuminate abnormalities. LG also designed the monitor with multiple sensors to help ensure an optimized diagnostic environment regardless of room conditions.

The Backlight Sensor will automatically adjust luminance to stabilize brightness for consistent imagery, while the Auto Luminance Sensor will help ensure screen brightness is optimized for the ambient lighting conditions. The built-in Presence Sensor automatically turns off the display when no motion is detected, saving energy and extending the monitor’s lifespan. Finally, the Front Sensor will enable automatic hardware calibration without additional equipment, which improves image quality and consistency while reducing required staff and ongoing costs.

Leaving no stone unturned, LG also carefully designed the monitor to have a lightweight body and one-click ergonomic stand, offering users convenient adjustments for height, tilt and pivot to help reduce chronic pain caused by long hours of viewing and poor posture.

At RSNA 2021, LG also is highlighting its full line of existing DXD detectors and diagnostic monitors. For more information on LG’s full line of medical display technology, please visit here.

*Pending FDA 510(k) notification. Each of these products is not available for sale in the United States and may not be ordered for sale, lease or distribution in commerce, or sold, leased or distributed in commerce, until proper authorization is obtained.

 

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy